Chiropractor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ara Cherik

Chiropractor Glendale, CA Chiropractor

NPI 1467877142 CMS profile 946081

1215 S Central Ave, Glendale, CA 91204

Open in the dashboard

General payments

$3,564

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ara Cherik of Glendale, CA is reported in the CMS Open Payments database as having received $3,564 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Chiropractor profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $927 38
2024 General $693 27
2023 General $404 20
2022 General $142 6
2021 General $590 28
2020 General $326 16
2019 General $483 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ara Cherik
  • Chiropractor median
  • Middle half of Chiropractor
  • National median

In program year 2025, general payments to Ara Cherik were reported at $927. Among 1,761 Chiropractor profiles paid that year, the median was $41 and the middle half received between $22 and $119.

Show as a table
Year Ara Cherik Chiropractor median Middle half National median
2019 $483 $51 $18–$114 $163
2020 $326 $31 $17–$81 $114
2021 $590 $38 $19–$119 $132
2022 $142 $47 $21–$122 $149
2023 $404 $41 $21–$125 $160
2024 $693 $41 $21–$124 $164
2025 $927 $41 $22–$119 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $920 37 payments
  2. AbbVie, Inc. $742 38 payments
  3. Kyowa Kirin, Inc. $241 12 payments
  4. Boston Scientific Corporation $193 4 payments
  5. EMD Serono, Inc. $183 6 payments
  6. ACADIA Pharmaceuticals Inc $153 7 payments
  7. Supernus Pharmaceuticals, Inc. $151 20 payments
  8. Argenx US, Inc. $97 4 payments
  9. Vanda Pharmaceuticals Inc. $95 4 payments
  10. Abbott Laboratories $84 4 payments
  11. Other $707 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,497 164 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $67 3 payments
Products named General payments · program years 2019–2025
  1. Zilbrysq $511 21 payments
  2. VRAYLAR $422 24 payments
  3. Rystiggo $299 12 payments
  4. QULIPTA $246 10 payments
  5. NOURIANZ $241 12 payments
  6. UBRELVY $195 9 payments
  7. NUPLAZID $129 6 payments
  8. OXTELLAR XR $127 16 payments
  9. GENERAL - PAIN MANAG $98 1 payment
  10. VYVGART $97 4 payments
  11. Other $1,083 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record